Search Results - Laura M. Spring

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Selection biases in the systematic collection of breast biobank specimens by Yael Bar, Gary X. Wang, Gabrielle E. Gioia, Geoffrey Fell, Shinn-Huey S. Chou, Veerle Bossuyt, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, Constance D. Lehman, Laura M. Spring

    Published in npj Breast Cancer (2025-08-01)
    Get full text
    Article


  2. 2

    Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer by Laura M. Spring, Shealagh L. Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J. Isakoff, Erica Mayer, Beverly Moy, Jeffrey G. Supko, Sara M. Tolaney, Aditya Bardia

    Published in npj Breast Cancer (2021-08-01)
    Get full text
    Article


  3. 3

    Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses by Siang-Boon Koh, Brian N. Dontchos, Veerle Bossuyt, Christine Edmonds, Simona Cristea, Nsan Melkonjan, Lindsey Mortensen, Annie Ma, Kassidy Beyerlin, Elyssa Denault, Elizabeth Niehoff, Taghreed Hirz, David B. Sykes, Franziska Michor, Michelle Specht, Constance Lehman, Leif W. Ellisen, Laura M. Spring

    Published in npj Precision Oncology (2021-09-01)
    Get full text
    Article


  4. 4

    Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER) by Laura M. Spring, Lauren Scarpetti, Arielle J. Medford, Andrzej Niemierko, Amy Comander, Therese Mulvey, Lowell Schnipper, Steven J. Isakoff, Beverly Moy, Seth A. Wander, Jennifer Shin, Zanta Ephrem, Anneke R. Laposta, Elyssa Denault, Elizabeth Abraham, Gayle Calistro, Ekaterina Kalashnikova, Angel Rodriguez, Minetta C. Liu, Alexey Aleshin, Jeffrey Peppercorn, Leif W. Ellisen, Aditya Bardia

    Published in npj Breast Cancer (2025-01-01)
    Get full text
    Article


  5. 5

    HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial by Zheqi Li, Otto Metzger Filho, Giuseppe Viale, Patrizia dell’Orto, Leila Russo, Marie-Anne Goyette, Avni Kamat, Denise A. Yardley, Vandana Gupta Abramson, Carlos L. Arteaga, Laura M. Spring, Kami Chiotti, Carol Halsey, Adrienne G. Waks, Tari A. King, Susan C. Lester, Jennifer R. Bellon, Eric P. Winer, Paul T. Spellman, Ian E. Krop, Kornelia Polyak

    Published in The Journal of Clinical Investigation (2024-04-01)
    Get full text
    Article


  6. 6

    A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer by Adrienne G. Waks, Neelam V. Desai, Tianyu Li, Philip D. Poorvu, Ann H. Partridge, Natalie Sinclair, Laura M. Spring, Meredith Faggen, Michael Constantine, Otto Metzger, Jillian Alberti, Julia Deane, Shoshana M. Rosenberg, Elizabeth Frank, Sara M. Tolaney, Ian E. Krop, Nadine M. Tung, Nabihah Tayob, Tari A. King, Elizabeth A. Mittendorf, Eric P. Winer

    Published in npj Breast Cancer (2022-05-01)
    Get full text
    Article


  7. 7

    Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer by Tanya E. Keenan, Jennifer L. Guerriero, Romualdo Barroso-Sousa, Tianyu Li, Tess O’Meara, Anita Giobbie-Hurder, Nabihah Tayob, Jiani Hu, Mariano Severgnini, Judith Agudo, Ines Vaz-Luis, Leilani Anderson, Victoria Attaya, Jihye Park, Jake Conway, Meng Xiao He, Brendan Reardon, Erin Shannon, Gerburg Wulf, Laura M. Spring, Rinath Jeselsohn, Ian Krop, Nancy U. Lin, Ann Partridge, Eric P. Winer, Elizabeth A. Mittendorf, David Liu, Eliezer M. Van Allen, Sara M. Tolaney

    Published in Nature Communications (2021-09-01)
    Get full text
    Article


Search Tools: